3 Global Generic Drug Maker, Over the Counter Medicines Exporter and Isobutylene Derivatives Maker Stocks With a Strong Future Roadmap: Dr. Reddy’s Laboratories, Marksans Pharma and Vinati Organics
- October 30, 2026
- Posted by: Lakshit Sharma
- Category: Best Stocks
Dr. Reddy’s Laboratories, Marksans Pharma and Vinati Organics: ROE of 11.1% to 14.0% and FY22 to FY26 revenue CAGR of 8.0% to 18.6%. Prices as of 29 Oct 2026.
Quick Answer
The three generic drug, OTC and isobutylene stocks to watch are Dr. Reddy’s Laboratories, Marksans Pharma and Vinati Organics. Their return on equity ranges from 11.1% to 14.0%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.0% to 18.6%. Vinati Organics has the highest return on equity at 14.0%, while Marksans Pharma has the fastest revenue growth at 18.6% a year. Prices are based on the 29 October 2026 close, and this article is educational, not investment advice.
Generic drug, OTC and isobutylene stocks give investors a way to track businesses that sit close to everyday demand in India. Dr. Reddy’s Laboratories, Marksans Pharma and Vinati Organics cover a global generic drug maker, an over the counter medicines exporter and an isobutylene derivatives maker.
This list covers three generic drug, OTC and isobutylene stocks with complete current figures: Dr. Reddy’s Laboratories, Marksans Pharma and Vinati Organics. Every figure comes from the latest reported financials and the 29 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Generic Drug, OTC and Isobutylene Stocks?
Generic drug, OTC and isobutylene stocks are listed companies that sell medicines in many countries, produce over the counter and prescription formulations for overseas markets and make specialty chemicals used in pharma, polymers and water treatment. Their earnings depend on approvals, export demand and product mix.
Generic Drug, OTC and Isobutylene Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Dr. Reddy’s Laboratories | 1,345 | 103,667 | 32.6 | 36.0 | 11.1 | 0.20 |
| Marksans Pharma | 315.35 | 12,994 | 24.9 | 35.7 | 13.8 | 0.11 |
| Vinati Organics | 1,038.6 | 11,582 | 25.8 | 35.1 | 14.0 | 0.00 |
On valuation, all three trade at a P/E below their industry P/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing generic drug, OTC and isobutylene stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Generic Drug, OTC and Isobutylene Stocks Have a Strong Roadmap in India?
Generic drug, OTC and isobutylene stocks have a strong roadmap in India because steady medicine demand abroad, wider generic use and niche chemistry leadership keep widening the market for these export focused companies.
- Global markets. Medicines reach buyers in many countries.
- Niche chemistry. Leading products support pricing strength.
- Steady demand. Health needs bring repeat orders.
Why Dr. Reddy’s Laboratories Features Among These Generic Drug, OTC and Isobutylene Stocks
Among the generic drug, OTC and isobutylene stocks on this list, Dr. Reddy’s Laboratories is a Hyderabad-based pharmaceutical company that makes generics, active ingredients and branded products for India and global markets, with a large presence in North America and Europe.
Revenue rose from Rs 22,030 crore in FY22 to Rs 35,059 crore in FY26, a compound annual growth rate of 12.3%. Net profit grew from Rs 2,182 crore in FY22 to Rs 4,158 crore in FY26, which works out to a compound annual growth rate of 17.5%.
The company has a return on equity of 11.1%, a debt to equity ratio of 0.20 and a market capitalisation of Rs 103,667 crore. The stock trades at a P/E of 32.6, below the industry P/E of 36.0.
Roadmap: The company is widening its product pipeline with complex generics, biosimilars and consumer health, while its domestic business adds steady growth. Investment in research supports a stream of new launches.
What to watch: Monitor launches of complex generics and the progress of biosimilar programmes.
Why Marksans Pharma Features Among These Generic Drug, OTC and Isobutylene Stocks
Among the pharma and chemical export shares on this list, Marksans Pharma is a Mumbai-based drug maker that produces over-the-counter and prescription formulations at plants in India and sells them in the United Kingdom, the United States, Australia and other markets.
The company has a return on equity of 13.8%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 12,994 crore. The stock trades at a P/E of 24.9, below the industry P/E of 35.7.
Revenue rose from Rs 1,533 crore in FY22 to Rs 3,033 crore in FY26, a compound annual growth rate of 18.6%. Net profit grew from Rs 187 crore in FY22 to Rs 420 crore in FY26, which works out to a compound annual growth rate of 22.5%. In the June 2026 quarter, revenue grew 38.5% year on year to Rs 866 crore.
Roadmap: The company is adding capacity and new products for regulated markets, which supports export growth. A focus on over-the-counter products gives it steady, repeat demand.
What to watch: Track export growth, new product approvals and plant utilisation.
Why Vinati Organics Features Among These Generic Drug, OTC and Isobutylene Stocks
Among the three companies on this list, Vinati Organics is a specialty chemicals company and the world’s leading maker of isobutylene derivatives such as IBB and ATBS, which are used in pharma, polymers and oilfield applications.
Revenue rose from Rs 1,676 crore in FY22 to Rs 2,280 crore in FY26, a compound annual growth rate of 8.0%. Net profit grew from Rs 347 crore in FY22 to Rs 444 crore in FY26, which works out to a compound annual growth rate of 6.4%.
In the June 2026 quarter, revenue grew 28.3% year on year to Rs 705 crore, while net profit rose 4.5% to Rs 109 crore. The company has a return on equity of 14.0%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 11,582 crore. The stock trades at a P/E of 25.8, below the industry P/E of 35.1.
Roadmap: The company holds a leading global position in its core products, and has been developing new chemistries that serve several industries. A strong balance sheet with no debt supports its capacity expansion programme.
What to watch: Monitor demand for ATBS and the ramp-up of new products and capacity.
Dr. Reddy’s Laboratories vs Marksans Pharma vs Vinati Organics on Key Financials
The table below sets the three generic drug, OTC and isobutylene stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Dr. Reddy’s Laboratories | 22,030 | 35,059 | 12.3% | 4,158 | 11.9% |
| Marksans Pharma | 1,533 | 3,033 | 18.6% | 420 | 13.8% |
| Vinati Organics | 1,676 | 2,280 | 8.0% | 444 | 19.5% |
Vinati Organics posts the highest return on equity in this group at 14.0%. Dr. Reddy’s Laboratories has the largest FY26 revenue at Rs 35,059 crore, and Marksans Pharma shows the fastest revenue growth with a 18.6% compound annual rate. A useful habit with generic drug, OTC and isobutylene stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in Generic Drug, OTC and Isobutylene Stocks
Every theme carries risks that deserve a check before any decision. For these generic drug, OTC and isobutylene stocks, the main points are: Long-term pharma and chemical export shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Regulatory approvals. Plant inspections and approvals can affect supplies.
- Currency moves. Export earnings move with the rupee.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter generic drug, OTC and isobutylene stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Generic Drug, OTC and Isobutylene Stocks
Generic drug, OTC and isobutylene stocks work best when investors track growth, valuation and return on equity side by side. Dr. Reddy’s Laboratories, Marksans Pharma and Vinati Organics each have a clear plan to grow. Based on the 29 October 2026 close, Dr. Reddy’s Laboratories trades at Rs 1,345, Marksans Pharma at Rs 315.35 and Vinati Organics at Rs 1,038.6.
Download the Univest iOS App or Univest Android App to track generic drug, OTC and isobutylene stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are generic drug, OTC and isobutylene stocks?
Ans. Generic drug, OTC and isobutylene stocks are listed companies that sell medicines in many countries, produce over the counter and prescription formulations for overseas markets and make specialty chemicals used in pharma, polymers and water treatment. Their earnings depend on approvals, export demand and product mix. This list looks at three of them, Dr. Reddy’s Laboratories, Marksans Pharma and Vinati Organics, using reported FY22 to FY26 financials and the 29 October 2026 closing prices.
Which generic drug, OTC and isobutylene stocks are covered in this list?
Ans. This list covers Dr. Reddy’s Laboratories, Marksans Pharma and Vinati Organics. Based on the 29 October 2026 close, Dr. Reddy’s Laboratories traded at Rs 1,345, Marksans Pharma at Rs 315.35 and Vinati Organics at Rs 1,038.6. Their return on equity ranges from 11.1% to 14.0%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.0% to 18.6%.
Why do generic drug, OTC and isobutylene stocks have a strong future roadmap in India?
Ans. Generic drug, OTC and isobutylene stocks have a strong roadmap in India because steady medicine demand abroad, wider generic use and niche chemistry leadership keep widening the market for these export focused companies. The main drivers are as follows. Global markets. Medicines reach buyers in many countries. Niche chemistry. Leading products support pricing strength. Steady demand. Health needs bring repeat orders. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Dr. Reddy’s Laboratories performed financially?
Ans. Revenue rose from Rs 22,030 crore in FY22 to Rs 35,059 crore in FY26, a compound annual growth rate of 12.3%. Net profit grew from Rs 2,182 crore in FY22 to Rs 4,158 crore in FY26, which works out to a compound annual growth rate of 17.5%. The company has a return on equity of 11.1%, a debt to equity ratio of 0.20 and a market capitalisation of Rs 103,667 crore. The stock trades at a P/E of 32.6, below the industry P/E of 36.0. Looking ahead, the company is widening its product pipeline with complex generics, biosimilars and consumer health, while its domestic business adds steady growth. Investment in research supports a stream of new launches.
How has Marksans Pharma performed financially?
Ans. Revenue rose from Rs 1,533 crore in FY22 to Rs 3,033 crore in FY26, a compound annual growth rate of 18.6%. Net profit grew from Rs 187 crore in FY22 to Rs 420 crore in FY26, which works out to a compound annual growth rate of 22.5%. In the June 2026 quarter, revenue grew 38.5% year on year to Rs 866 crore. The company has a return on equity of 13.8%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 12,994 crore. The stock trades at a P/E of 24.9, below the industry P/E of 35.7. Looking ahead, the company is adding capacity and new products for regulated markets, which supports export growth. A focus on over-the-counter products gives it steady, repeat demand.
How has Vinati Organics performed financially?
Ans. Revenue rose from Rs 1,676 crore in FY22 to Rs 2,280 crore in FY26, a compound annual growth rate of 8.0%. Net profit grew from Rs 347 crore in FY22 to Rs 444 crore in FY26, which works out to a compound annual growth rate of 6.4%. In the June 2026 quarter, revenue grew 28.3% year on year to Rs 705 crore, while net profit rose 4.5% to Rs 109 crore. The company has a return on equity of 14.0%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 11,582 crore. The stock trades at a P/E of 25.8, below the industry P/E of 35.1. Looking ahead, the company holds a leading global position in its core products, and has been developing new chemistries that serve several industries. A strong balance sheet with no debt supports its capacity expansion programme.
What risks should investors check before buying generic drug, OTC and isobutylene stocks?
Ans. Investors should check a few risks before buying generic drug, OTC and isobutylene stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Currency moves. Export earnings move with the rupee. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of generic drug, OTC and isobutylene stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 29 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.